Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences announced that the FDA has approved an aortic valve conduit for use during bio-Bentall ...
IRVINE, Calif., July 15, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
Edwards Lifesciences Corp. has scored an approval from the U.S. FDA for the Konect Resilia aortic valved conduit, a ready-to-implant solution for bio-Bentall procedures.
Edwards Lifesciences Corp. has scored an approval from the U.S. FDA for the Konect Resilia aortic valved conduit, a ready-to-implant solution for bio-Bentall procedures. The move represents an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results